Literature DB >> 1904068

Inhibition of immune functions by antiviral drugs.

W Heagy1, C Crumpacker, P A Lopez, R W Finberg.   

Abstract

Immune functions were evaluated in vitro for PBMC isolated from healthy donors and cultured with the antiviral agents, 3'-azido-3'-deoxythymidine (AZT), ribavirin, ganciclovir, 2'3'-dideoxyinosine (ddI), or acyclovir. To identify methods for assessing the effects of antiviral drugs on immune cells, the PBMC response to mitogens, Con A, or phytohemagglutinin was evaluated from measurements of [3H]thymidine and [14C]-leucine incorporation, cell growth, cellular RNA, DNA, and protein levels, and the PBMC proliferative cycle (i.e., progression from G0----G1----S----G2 + M). At clinically relevant concentrations, AZT, ribavirin, or ganciclovir diminished PBMC responsiveness to mitogen. The numbers of proliferating cells in G1, S, and G2 + M phases of the cell cycle, DNA content, and [3H]thymidine uptake were decreased in cultures treated with AZT, ribavirin, or ganciclovir. AZT or ribavirin but not ganciclovir reduced RNA and protein in the cultures and inhibited cell growth. Whereas AZT, ribavirin, or ganciclovir were antiproliferative, ddI or acyclovir had little, if any, effect on PBMC mitogenesis. The inhibitory effects of antivirals on immune cells may contribute to the immune deterioration observed in patients following prolonged use of the drugs.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1904068      PMCID: PMC296943          DOI: 10.1172/JCI115217

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  37 in total

1.  Clinical studies with ribavirin.

Authors:  P J Edelson
Journal:  Pediatr Infect Dis J       Date:  1990-09       Impact factor: 2.129

2.  Immunosuppressive effects of ganciclovir on in vitro lymphocyte responses.

Authors:  R A Bowden; J Digel; E C Reed; J D Meyers
Journal:  J Infect Dis       Date:  1987-12       Impact factor: 5.226

3.  Relationship between RNA content and progression of lymphocytes through S phase of cell cycle.

Authors:  Z Darzynkiewicz; D Evenson; L Staiano-Coico; T Sharpless; M R Melamed
Journal:  Proc Natl Acad Sci U S A       Date:  1979-01       Impact factor: 11.205

4.  Cytomegalovirus-specific lymphocyte proliferation and in vitro cytomegalovirus IgG synthesis for diagnosis of cytomegalovirus infections after bone marrow transplantation.

Authors:  P Ljungman; B Lönnqvist; G Gahrton; O Ringdén; B Wahren
Journal:  Blood       Date:  1986-07       Impact factor: 22.113

5.  Inhibition of bone marrow myelopoiesis and erythropoiesis in vitro by anti-retroviral nucleoside derivatives.

Authors:  M Johnson; T Caiazzo; J M Molina; R Donahue; J Groopman
Journal:  Br J Haematol       Date:  1988-10       Impact factor: 6.998

6.  Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex.

Authors:  R Yarchoan; R W Klecker; K J Weinhold; P D Markham; H K Lyerly; D T Durack; E Gelmann; S N Lehrman; R M Blum; D W Barry
Journal:  Lancet       Date:  1986-03-15       Impact factor: 79.321

7.  Lassa fever. Effective therapy with ribavirin.

Authors:  J B McCormick; I J King; P A Webb; C L Scribner; R B Craven; K M Johnson; L H Elliott; R Belmont-Williams
Journal:  N Engl J Med       Date:  1986-01-02       Impact factor: 91.245

8.  The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3'-azido-2',3'-dideoxythymidine and 2',3'-dideoxycytidine are highly dependent on the cell species.

Authors:  J Balzarini; R Pauwels; M Baba; P Herdewijn; E de Clercq; S Broder; D G Johns
Journal:  Biochem Pharmacol       Date:  1988-03-01       Impact factor: 5.858

9.  A pilot study of low-dose zidovudine in human immunodeficiency virus infection.

Authors:  A C Collier; S Bozzette; R W Coombs; D M Causey; D A Schoenfeld; S A Spector; C B Pettinelli; G Davies; D D Richman; J M Leedom
Journal:  N Engl J Med       Date:  1990-10-11       Impact factor: 91.245

10.  Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.

Authors:  P A Furman; J A Fyfe; M H St Clair; K Weinhold; J L Rideout; G A Freeman; S N Lehrman; D P Bolognesi; S Broder; H Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

View more
  23 in total

Review 1.  Treatment of recurrent hepatitis C following liver transplantation.

Authors:  T Bizollon; C Ducerf; J Baulieux; C Trepo
Journal:  Curr Gastroenterol Rep       Date:  1999 Feb-Mar

2.  Comparison of ribavirin and oseltamivir in reducing mortality and lung injury in mice infected with mouse adapted A/California/04/2009 (H1N1).

Authors:  Sotirios G Zarogiannis; James W Noah; Asta Jurkuvenaite; Chad Steele; Sadis Matalon; Diana L Noah
Journal:  Life Sci       Date:  2012-01-16       Impact factor: 5.037

3.  Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation.

Authors:  Katia Perruccio; Antonella Tosti; Emanuela Burchielli; Fabiana Topini; Loredana Ruggeri; Alessandra Carotti; Marusca Capanni; Elena Urbani; Antonella Mancusi; Franco Aversa; Massimo F Martelli; Luigina Romani; Andrea Velardi
Journal:  Blood       Date:  2005-08-25       Impact factor: 22.113

Review 4.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

5.  Comparison of the chronic effects of ribavirin and caffeic acid phenethyl ester (CAPE) on pancreatic damage and hepatotoxicity.

Authors:  Sedat Motor; Harun Alp; Serkan Senol; Neslihan Pınar; Vicdan Köksaldı Motor; Ibrahim Kaplan; Ayşe Alp; Cumali Gökçe
Journal:  Int J Clin Exp Med       Date:  2014-04-15

6.  Effect of zidovudine on the primary cytolytic T-lymphocyte response and T-cell effector function.

Authors:  S Francke; C G Orosz; K A Hayes; L E Mathes
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

7.  Evidence that high-dosage zidovudine at time of retrovirus exposure reduces antiviral efficacy.

Authors:  L E Mathes; K A Hayes; G Kociba
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

8.  Controversies' clarification regarding ribavirin efficacy in measles and coronaviruses: Comprehensive therapeutic approach strictly tailored to COVID-19 disease stages.

Authors:  George D Liatsos
Journal:  World J Clin Cases       Date:  2021-07-06       Impact factor: 1.337

9.  Lack of immunotoxicity of saquinavir (Ro 31-8959) used alone or in double or triple combination with AZT and ddC.

Authors:  M Viora; G Di Genova; M G Quaranta; M Boirivant; B Camponeschi
Journal:  J Clin Immunol       Date:  1998-09       Impact factor: 8.317

Review 10.  Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection.

Authors:  D Faulds; R N Brogden
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.